Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Sweden

European Research Council grant · Finished

MUC2GO Novel treatments for the mucus accumulation at chronic lung diseases

Coordinator
Goeteborgs Universitet, Sweden
Runs
1 March 2023 to 31 August 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101100663

What the project is doing

In the project's own words, from its summary on CORDIS.

The aim of this proof of concept is to develop novel therapies based on the discoveries made during the AdvERC grant on mucus and mucins in the lung and intestine. The discovery that the XX protein is absent or almost absent in healthy individuals and animals and heavily increased in human COPD and induced lung disease in animals made us study this. During the ERC grant we discoverd that XX is anchoring and attaching the lung mucus by forming a cap on the accumulated mucus.

In the absence of XX the mucus is non-attached and transported even better than normal. We have now determined the detailed molecular structure of the XX and learnt how this protein can form long, large polymers by non-covalent interactions. We will now develop inhibitory peptides, proteins, antibodies or small organic molecules to be used as therapeutic drugs for detaching the attached mucus at Cystic Fibrosis, Chronic bronchitis, COPD, and other lung diseases with mucus accumulation.

Topics

Who is involved

OrganisationCityCountryRole
Goeteborgs UniversitetGoeteborgSwedenCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI